Overview
Compare with Anika Therapeutics, Inc., Intersect ENT or Beta Bionics, Inc., or pick any stock.
- TickerOSUR on Nasdaq1
- IndustrySurgical & Medical Instruments & Apparatus1
- HeadquartersBethlehem, Pennsylvania1
- Incorporated inDE2
- Business address220 E First St, Bethlehem, Pa 180152
- Filer categoryAccelerated filer2
See how the biggest companies compare on our leaderboards
OTI transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
41.9%Gross margin5
-62.6%Operating margin5
-59.8%Net margin5
-38.1%Revenue growth, 20255
-20.2%Return on equity5
-$53.2MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product And Services brought in 95% of the revenue ORASURE TECHNOLOGIES INC broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Product And Services | $402.2M | $184.6M | $109.1M |
| Other Revenues | $3.2M | $1.2M | $6.0M |
Regions
United States brought in 68% of the revenue ORASURE TECHNOLOGIES INC broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $361.7M | $139.2M | $78.3M |
| Africa | $29.3M | $32.7M | $24.0M |
| Europe | $8.1M | $8.4M | $7.4M |
| Other Foreign Countries | $6.4M | $5.5M | $5.4M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue58¢$66.8M
- Research and development37¢$42.5M
- Other costs3¢$3.9M
- Income tax2¢$1.8M
Out of $115.0M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenue | $115.0M | $185.8M | $405.5M |
| COST OF PRODUCTS AND SERVICES SOLD | $66.8M | $106.4M | $233.8M |
| Gross profit | $48.2M | $79.4M | $171.7M |
| Research and development | $42.5M | $26.0M | $33.7M |
| Sales and marketing | $26.1M | $31.0M | $36.3M |
| General and administrative | $47.7M | $46.2M | $58.2M |
| Loss on impairments | $0 | $4.4M | $10.8M |
| Change in the estimated fair value of acquisition-related contingent consideration | $4.6M | $0 | -$99.0K |
| Gain on sale of assets | -$725.0K | $0 | $0 |
| Total operating expenses | $120.2M | $107.6M | $139.0M |
| Operating (loss) income | -$72.0M | -$28.2M | $32.7M |
| OTHER INCOME | $7.4M | $12.2M | $23.6M |
| (Loss) income before income taxes and equity investment | -$64.6M | -$16.0M | $56.3M |
| INCOME TAX EXPENSE | $1.8M | $1.8M | $2.6M |
| (LOSS) INCOME BEFORE EQUITY INVESTMENT | -$66.4M | -$17.8M | $53.7M |
| LOSS ON EQUITY INVESTMENT | -$2.3M | -$1.7M | $0 |
| NET (LOSS) INCOME | -$68.7M | -$19.5M | $53.7M |
| Basic earnings per share (in US dollars per share) | -$0.94 | -$0.26 | $0.73 |
| Diluted earnings per share (in US dollars per share) | -$0.94 | -$0.26 | $0.72 |
| Basic weighted average number of shares outstanding (in shares) | 73.5M shares | 74.4M shares | 73.3M shares |
| Diluted weighted average number of shares outstanding (in shares) | 73.5M shares | 74.4M shares | 74.4M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $199.3M | $267.8M | ||
| Accounts receivable, net of allowance for doubtful accounts of $188 and $774 | $22.2M | $23.8M | $40.2M | |
| Inventories | $31.1M | $34.2M | ||
| Prepaid expenses | $5.2M | $4.0M | ||
| Other current assets | $4.1M | $3.5M | ||
| Total current assets | $261.9M | $333.2M | ||
| Property, plant and equipment, net of accumulated depreciation | $39.2M | $45.1M | ||
| Operating right-of-use assets, net | $12.0M | $13.4M | ||
| Finance right-of-use assets, net | $146.0K | $145.0K | ||
| Net | $19.0M | $17.4M | ||
| Goodwill | $43.4M | $40.3M | $35.7M | |
| Investment in equity method investee | $26.0M | $28.3M | ||
| Deferred tax asset | $271.0K | $156.0K | ||
| Other noncurrent assets | $1.3M | $1.5M | ||
| Total noncurrent assets | $141.3M | $146.4M | ||
| TOTAL ASSETS | $403.2M | $479.7M | ||
| Accounts payable | $6.5M | $8.2M | ||
| Deferred revenue | $1.5M | $3.0M | $1.6M | |
| Accrued expenses and other current liabilities | $11.1M | $20.2M | ||
| Finance lease liability | $63.0K | $41.0K | ||
| Operating lease liability | $2.2M | $2.1M | ||
| Current portion | $18.4M | $0 | ||
| Total current liabilities | $39.8M | $33.5M | ||
| Finance lease liability | $100.0K | $113.0K | ||
| Operating lease liability | $10.9M | $12.3M | ||
| Long-term portion | $9.3M | $22.9M | ||
| Other noncurrent liabilities | $2.2M | $494.0K | ||
| Total noncurrent liabilities | $22.5M | $35.8M | ||
| TOTAL LIABILITIES | $62.3M | $69.3M | ||
| Preferred stock, par value $0.000001, 25,000 shares authorized, none issued | $0 | $0 | ||
| Common stock, par value $0.000001, 120,000 shares authorized, 70,391 and 74,598 shares issued and outstanding | $0 | $0 | ||
| Additional paid-in capital | $531.4M | $538.1M | ||
| Accumulated other comprehensive loss | -$18.4M | -$24.4M | ||
| Accumulated deficit | -$172.2M | -$103.4M | ||
| Total stockholders' equity | $340.8M | $410.3M | $430.7M | $364.4M |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $403.2M | $479.7M | ||
| Allowance for doubtful accounts | $188.0K | $774.0K | $1.2M | |
| Preferred stock, par value (in US dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 25.0M shares | 25.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in US dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 120.0M shares | 120.0M shares | ||
| Common stock, shares issued (in shares) | 70.4M shares | 74.6M shares | ||
| Common stock, shares outstanding (in shares) | 70.4M shares | 74.6M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $199.3M | $267.8M | ||
| Accounts receivable, net of allowance for doubtful accounts of $188 and $774 | $22.2M | $23.8M | $40.2M | |
| Inventories | $31.1M | $34.2M | ||
| Prepaid expenses | $5.2M | $4.0M | ||
| Other current assets | $4.1M | $3.5M | ||
| Total current assets | $261.9M | $333.2M | ||
| Property, plant and equipment, net of accumulated depreciation | $39.2M | $45.1M | ||
| Operating right-of-use assets, net | $12.0M | $13.4M | ||
| Finance right-of-use assets, net | $146.0K | $145.0K | ||
| Net | $19.0M | $17.4M | ||
| Goodwill | $43.4M | $40.3M | $35.7M | |
| Investment in equity method investee | $26.0M | $28.3M | ||
| Deferred tax asset | $271.0K | $156.0K | ||
| Other noncurrent assets | $1.3M | $1.5M | ||
| Total noncurrent assets | $141.3M | $146.4M | ||
| TOTAL ASSETS | $403.2M | $479.7M | ||
| Accounts payable | $6.5M | $8.2M | ||
| Deferred revenue | $1.5M | $3.0M | $1.6M | |
| Accrued expenses and other current liabilities | $11.1M | $20.2M | ||
| Finance lease liability | $63.0K | $41.0K | ||
| Operating lease liability | $2.2M | $2.1M | ||
| Current portion | $18.4M | $0 | ||
| Total current liabilities | $39.8M | $33.5M | ||
| Finance lease liability | $100.0K | $113.0K | ||
| Operating lease liability | $10.9M | $12.3M | ||
| Long-term portion | $9.3M | $22.9M | ||
| Other noncurrent liabilities | $2.2M | $494.0K | ||
| Total noncurrent liabilities | $22.5M | $35.8M | ||
| TOTAL LIABILITIES | $62.3M | $69.3M | ||
| Preferred stock, par value $0.000001, 25,000 shares authorized, none issued | $0 | $0 | ||
| Common stock, par value $0.000001, 120,000 shares authorized, 70,391 and 74,598 shares issued and outstanding | $0 | $0 | ||
| Additional paid-in capital | $531.4M | $538.1M | ||
| Accumulated other comprehensive loss | -$18.4M | -$24.4M | ||
| Accumulated deficit | -$172.2M | -$103.4M | ||
| Total stockholders' equity | $340.8M | $410.3M | $430.7M | $364.4M |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $403.2M | $479.7M | ||
| Allowance for doubtful accounts | $188.0K | $774.0K | $1.2M | |
| Preferred stock, par value (in US dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 25.0M shares | 25.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in US dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 120.0M shares | 120.0M shares | ||
| Common stock, shares issued (in shares) | 70.4M shares | 74.6M shares | ||
| Common stock, shares outstanding (in shares) | 70.4M shares | 74.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net (loss) income | -$68.7M | -$19.5M | $53.7M |
| Stock-based compensation | $10.1M | $11.9M | $10.7M |
| Depreciation and amortization | $10.2M | $10.9M | $20.9M |
| Loss on impairments | $0 | $4.4M | $10.8M |
| Other non-cash amortization | -$222.0K | -$564.0K | $3.0K |
| Provision for credit losses | -$65.0K | $71.0K | -$462.0K |
| Unrealized foreign currency loss (gain) | $365.0K | -$263.0K | $103.0K |
| Interest expense on finance leases | $8.0K | $22.0K | $51.0K |
| Loss on equity investment | $2.3M | $1.7M | $0 |
| Deferred income taxes | $1.9M | -$657.0K | $102.0K |
| (Gain) loss on sale of fixed assets | -$725.0K | $563.0K | $0 |
| Change in the estimated fair value of acquisition-related contingent consideration | $4.6M | $0 | -$99.0K |
| Payment of acquisition-related contingent consideration | $0 | $0 | -$19.0K |
| Accounts receivable | $1.9M | $15.9M | $31.1M |
| Inventories | $3.6M | $13.1M | $48.2M |
| Prepaid expenses and other assets | -$2.4M | $4.1M | -$2.5M |
| Accounts payable | -$1.7M | -$7.6M | -$27.0M |
| Deferred revenue | -$1.5M | -$219.0K | -$730.0K |
| Accrued expenses and other liabilities | -$8.7M | -$6.4M | -$3.4M |
| Net cash (used in) provided by operating activities | -$49.0M | $27.4M | $141.6M |
| Purchases of short-term investments | $0 | -$53.2M | -$74.7M |
| Proceeds from maturities and redemptions of investments | $0 | $53.1M | $102.4M |
| Purchase of equity method investee | $0 | -$30.0M | $0 |
| Acquisition of business, net of cash acquired | -$3.6M | -$5.0M | $0 |
| Proceeds from sale of assets | $1.0M | $0 | $0 |
| Purchases of property and equipment | -$4.2M | -$3.8M | -$5.8M |
| Purchase of property and equipment under government contracts | $0 | $0 | -$4.5M |
| Proceeds from funding under government contracts | $0 | $0 | $48.7M |
| Net cash (used in) provided by investing activities | -$6.8M | -$39.0M | $66.2M |
| Cash payments for lease liabilities | -$61.0K | -$842.0K | -$1.3M |
| Proceeds from exercise of stock options | $0 | $214.0K | $269.0K |
| Repurchase of common stock | -$15.0M | $0 | $0 |
| Payment of acquisition-related contingent consideration | $0 | $0 | $46.0K |
| Payment of taxes related to net share settlement of equity awards | -$1.8M | -$3.5M | -$1.9M |
| Net cash used in financing activities | -$16.9M | -$4.2M | -$3.0M |
| EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH | $4.3M | -$6.8M | $1.7M |
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | -$68.5M | -$22.6M | $206.4M |
No quarter-by-quarter statement was filed.
Corporate structure
ORASURE TECHNOLOGIES INC sits at the top of its group. 5 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of ORASURE TECHNOLOGIES INC
- Islet Management, LP Filed SCHEDULE 13D on ORASURE TECHNOLOGIES INC, latest Sep 17, 2026
- GAGNON SECURITIES LLC Filed SCHEDULE 13G on ORASURE TECHNOLOGIES INC, latest Aug 12, 2026 (4 filings since Nov 17, 2025)
- PRIVATE MANAGEMENT GROUP INC Filed SCHEDULE 13G/A on ORASURE TECHNOLOGIES INC, latest Jul 31, 2026 (3 filings since May 5, 2025)
- VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on ORASURE TECHNOLOGIES INC, latest Apr 30, 2026
- Altai Capital Management, L.P. Filed SCHEDULE 13D/A on ORASURE TECHNOLOGIES INC, latest Apr 20, 2026 (5 filings since Sep 9, 2025)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on ORASURE TECHNOLOGIES INC, latest Mar 27, 2026 (6 filings since Feb 10, 2022)
- DIMENSIONAL FUND ADVISORS LP Filed SCHEDULE 13G/A on ORASURE TECHNOLOGIES INC, latest Oct 9, 2025 (2 filings since Feb 9, 2024)
- EARNEST PARTNERS LLC Filed SCHEDULE 13G/A on ORASURE TECHNOLOGIES INC, latest Sep 3, 2025 (2 filings since Feb 8, 2022)
- Camber Capital Management LP Filed SCHEDULE 13G/A on ORASURE TECHNOLOGIES INC, latest May 15, 2025 (3 filings since Nov 8, 2021)
- BlackRock Filed SCHEDULE 13G/A on ORASURE TECHNOLOGIES INC, latest Apr 23, 2025 (6 filings since Jan 28, 2022)
- Neuberger Berman Filed SCHEDULE 13G on ORASURE TECHNOLOGIES INC, latest Apr 4, 2025 (3 filings since Oct 4, 2024)
- MANAGED ACCOUNT ADVISORS LLC Filed SC 13G/A on ORASURE TECHNOLOGIES INC, latest Feb 7, 2023 (2 filings since Jan 26, 2022)
- ORASURE TECHNOLOGIES INC Bethlehem, Pennsylvania
- BioMedomics, Inc. Subsidiary · Delaware, United States
- DNA Genotek Inc. Subsidiary · Canada
- Sense Biodetection Limited Subsidiary · United Kingdom
- Sherlock Biosciences, Inc Subsidiary · Delaware, United States
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What ORASURE TECHNOLOGIES INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $102.1M5 Dec 31, 2025 | $111.0M5 Dec 31, 2024 | −8.1% |
| Accumulated depreciation | $62.9M5 Dec 31, 2025 | $65.9M5 Dec 31, 2024 | −4.6% |
| Property and equipment, net | $39.2M5 Dec 31, 2025 | $45.1M5 Dec 31, 2024 | −13.1% |
| Finance-lease assets | $146.0K5 Dec 31, 2025 | $145.0K5 Dec 31, 2024 | +0.7% |
| Operating-lease assets (leased space) | $12.0M5 Dec 31, 2025 | $13.4M5 Dec 31, 2024 | −10.8% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $199.3M5 Dec 31, 2025 | $267.8M5 Dec 31, 2024 | −25.6% |
| Debt securities available for sale | $05 Dec 31, 2025 | $05 Dec 31, 2024 |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $43.4M5 Dec 31, 2025 | $40.3M5 Dec 31, 2024 | +7.5% |
| Intangible assets, net (excluding goodwill) | $19.0M5 Dec 31, 2025 | $17.4M5 Dec 31, 2024 | +9.2% |
| Finite-lived intangibles, gross | $29.2M5 Dec 31, 2025 | $32.8M5 Dec 31, 2024 | −11.0% |
| Accumulated amortization | $27.2M5 Dec 31, 2025 | $32.4M5 Dec 31, 2024 | −16.1% |
| Finite-lived intangibles, net | $2.0M5 Dec 31, 2025 | $435.0K5 Dec 31, 2024 | +370.3% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $31.1M5 Dec 31, 2025 | $34.2M5 Dec 31, 2024 | −9.2% |
| Raw materials | $14.8M5 Dec 31, 2025 | $17.0M5 Dec 31, 2024 | −12.8% |
| Work in process | $56.0K5 Dec 31, 2025 | $420.0K5 Dec 31, 2024 | −86.7% |
| Finished goods | $14.2M5 Dec 31, 2025 | $13.9M5 Dec 31, 2024 | +2.3% |
Properties, in its own words
The Company owns a 31,700 square foot facility that houses its primary corporate office, sales and marketing, research and development, human resources, and regulatory and quality offices. The Company also owns a 48,000 square foot facility and a 33,500 square foot facility which are used for manufacturing activities. The Company also leases a 139,000 square foot manufacturing facility. Each of these facilities is located in Bethlehem, Pennsylvania. The Company's subsidiary, DNAG, also leases a 36,000 square foot facility in Ottawa, Canada, which is used as its primary corporate office and houses sales and marketing, manufacturing, distribution, research and development, and regulatory and quality operations. The Company's subsidiary, Sherlock, leases various facilities in the United Kingdom totaling approximately 37,600 square feet, as well as outside Boston, Massachusetts, totaling approximately 5,000 square feet. These facilities house Sherlock's corporate offices, production, and research and development activities. The Company's subsidiary, BioMedomics, leases a building in North Carolina totaling approximately 2,000 square feet. The facility houses BioMedomics' corporate offices, production, and research and development activities.
The Company believes that the facilities described above are adequate for its current requirements.
Item 2 of the 10-K filed Mar 9, 2026.4
Leadership
Who has led ORASURE TECHNOLOGIES INC, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerManner Carrie Eglinton Jun 6, 2022 to now13
- PresidentKathleen Gallagher Weber Jan 7, 2022 to Feb 3, 202214
- PresidentLisa Nibauer Jan 7, 2022 to May 12, 202215
- PresidentManner Carrie Eglinton Jun 6, 2022 to now13
- Chief financial officerKenneth J. McGrath Aug 15, 2022 to now16
- Chief financial officerScott Gleason Sep 20, 2021 to May 24, 202217
- Chief financial officerRoberto Cuca Jun 11, 2018 to May 10, 202118
- Chief financial officerRonald H. Spair Jan 25, 2006 to Jun 11, 201819
- Chief operating officerRonald H. Spair Oct 3, 2006 to Jun 11, 201820
Board members and other officers (35)
- DirectorNancy J. Gagliano Apr 5, 2022 to Apr 5, 202221
- EVP & BU Lead - InfectiousLisa Nibauer May 13, 2020 to May 13, 202122
- EVP & BU Lead - MolecularKathleen Gallagher Weber Jan 4, 2019 to Mar 4, 202523
- VP, Finance and ControllerMichele Marie Miller Nov 2, 2018 to now24
- SVP, Research and DevelopmentEric Whitters Mar 4, 2014 to Feb 5, 201525
- EVP, Marketing and SalesAnthony Zezzo Ii. Jan 4, 2011 to Feb 4, 202026
- VP, Marketing and SalesManuel O. Mendez Nov 12, 2009 to Jan 27, 201027
- Exec. VP - Sales & Mktg.Joseph E. Zack Jan 25, 2006 to Feb 5, 200828
- VP & ControllerMark L. Kuna Jan 25, 2006 to Oct 24, 201829
- Exec. VP - OperationsP. Michael Formica Jan 25, 2006 to Aug 21, 200930
- Exec. VP and CSOStephen R. Lee Sep 26, 2006 to Feb 5, 201431
- Board memberJohn D. Bertrand May 14, 2026 to now32
- Board memberJohn P. Kenny Sep 10, 2024 to now33
- Board memberRobert W. McMahon Aug 1, 2023 to now34
- Board memberManner Carrie Eglinton Jun 6, 2022 to now13
- Board memberAnne Clem Whitaker Nov 10, 2021 to May 17, 202335
- Board memberNancy J. Gagliano Nov 23, 2021 to now36
- Board memberDavid Shulkin Apr 8, 2020 to now37
- Board memberLelio Marmora Jun 2, 2020 to now38
- Board memberJames A. Datin Aug 14, 2019 to May 16, 202439
- Board memberAradhana Sarin Feb 2, 2018 to May 22, 201940
- Board memberMara G. Aspinall Jun 22, 2017 to now41
- Board memberEamonn P. Hobbs Mar 23, 2016 to May 18, 202242
- Board memberGerald M. Ostrov Nov 14, 2011 to May 22, 201443
- Board memberCharles W. Patrick Jan 10, 2006 to May 19, 202044
- Board memberDouglas G. Watson Jan 25, 2006 to Nov 16, 201645
- Board memberFrank G. Hausmann Jan 25, 2006 to Feb 5, 200746
- Board memberRoger L. Pringle Jan 25, 2006 to May 17, 201747
- Board memberRonny B. Lancaster Jan 25, 2006 to Aug 29, 202248
- Board memberJack Goldstein May 23, 2006 to Feb 3, 201149
- Board memberRonald H. Spair Oct 3, 2006 to Jun 11, 201820
- Board memberMichael Celano Oct 5, 2006 to Aug 16, 202250
- General counselAgnieszka Gallagher Nov 30, 2021 to Feb 3, 202251
- General counselJack E. Jerrett Jan 25, 2006 to Jan 3, 202252
- General counselStephen R. Lee Jan 25, 2006 to Jan 25, 200653
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- BioMedomics, Inc. Delaware3
- DNA Genotek Inc. Canada3
- Sense Biodetection Limited England and Wales3
- Sherlock Biosciences, Inc Delaware3
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Aug 5, 20268-K Results of operations54
- Jun 11, 20268-K Other events55
- Jun 3, 20268-K Executive or director change; Bylaws or fiscal year changed; Shareholder vote56
- May 6, 20268-K Results of operations; Regulation FD disclosure57
- Apr 17, 20268-K Entered a material agreement; Executive or director change; Regulation FD disclosure58
- Mar 30, 20268-K Regulation FD disclosure59
- Mar 5, 20268-K Executive or director change60
- Feb 25, 20268-K Results of operations; Regulation FD disclosure61
- Jan 5, 20268-K Regulation FD disclosure; Other events62
- Dec 1, 20258-K Other events63
- Nov 5, 20258-K Results of operations; Regulation FD disclosure64
- Oct 28, 20258-K Executive or director change65
- Jun 6, 2022New chief executive Manner Carrie Eglinton becomes CEO13
Calendar
Coming up
- Nov 4, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.17) a share, on Nov 5, 2025.66
When it reported results
- Aug 5, 2026Reported quarterly or annual results54
- May 6, 2026Reported quarterly or annual results57
- Feb 25, 2026Reported quarterly or annual results61
- Nov 5, 2025Reported quarterly or annual results64
- Aug 5, 2025Reported quarterly or annual results67
- May 7, 2025Reported quarterly or annual results68
- Feb 25, 2025Reported quarterly or annual results69
- Nov 6, 2024Reported quarterly or annual results70
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
315 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 59 major events, 144 insider forms, 38 large holders, 54 other. The latest 20:
- Oct 1, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Sep 17, 2026SCHEDULE 13D EDGAR
- Sep 9, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Aug 12, 2026SCHEDULE 13G EDGAR
- Aug 7, 2026S-8 EDGAR
- Aug 7, 202610-Q EDGAR
- Aug 5, 20268-K EDGAR
- Jul 31, 2026SCHEDULE 13G/A EDGAR
- Jun 30, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Jun 11, 20268-K EDGAR
- Jun 5, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Jun 5, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Jun 5, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Jun 5, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Jun 5, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Jun 5, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Jun 3, 20268-K EDGAR
- May 14, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- May 14, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- May 14, 20263 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
The 315 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
21 open-market trades by officers, directors and large owners since October 2021: 19 buys and 2 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 14, 2026 | Boyd Steven KyleDirector | Buy | 25,000 | $2.99 | $74.8K | Form 4 |
| May 13, 2026 | Boyd Steven KyleDirector | Buy | 25,000 | $3.02 | $75.5K | Form 4 |
| May 12, 2026 | Boyd Steven KyleDirector | Buy | 25,000 | $2.98 | $74.5K | Form 4 |
| Mar 20, 2026 | McGrath Kenneth JChief Financial Officer | Buy | 32,300 | $2.93 | $94.6K | Form 4 |
| Mar 20, 2026 | EGLINTON MANNER CARRIEPresident & CEO | Buy | 32,300 | $2.93 | $94.6K | Form 4 |
| Mar 13, 2026 | McGrath Kenneth JChief Financial Officer | Buy | 22,021 | $3.00 | $66.1K | Form 4 |
| Mar 13, 2026 | EGLINTON MANNER CARRIEPresident & CEO | Buy | 22,022 | $3.00 | $66.1K | Form 4 |
| Nov 28, 2025 | Gagliano Nancy JDirector | Buy | 2,100 | $2.37 | $5.0K | Form 4 |
| Feb 28, 2025 | EGLINTON MANNER CARRIEPresident & CEO | Buy | 28,670 | $3.49 | $100.1K | Form 4 |
| Feb 27, 2025 | Gagliano Nancy JDirector | Buy | 12,750 | $3.08 | $39.3K | Form 4 |
| Feb 27, 2025 | EGLINTON MANNER CARRIEPresident & CEO | Buy | 78,625 | $3.15 | $247.7K | Form 4 |
| Feb 27, 2025 | Kenny John P.Director | Buy | 47,659 | $3.17 | $151.1K | Form 4 |
| Feb 27, 2025 | McGrath Kenneth JChief Financial Officer | Buy | 64,000 | $3.15 | $201.6K | Form 4 |
| Feb 27, 2025 | Marmora LelioDirector | Buy | 7,000 | $3.06 | $21.4K | Form 4 |
| Dec 19, 2023 | Weber Kathleen GallagherChief Product Officer | Sale | 24,129 | $8.05 | $194.2K | Form 4 |
| Aug 15, 2023 | Anthony Michele MarieSVP Finance & CAO | Sale | 1,758 | $6.50 | $11.4K | Form 4 |
| May 30, 2023 | McGrath Kenneth JChief Financial Officer | Buy | 100,000 | $4.93 | $493.0K | Form 4 |
| Aug 26, 2022 | LANCASTER RONNY BDirector | Buy | 50,000 | $4.00 | $200.0K | Form 4 |
| Aug 25, 2022 | Aspinall Mara G.Director | Buy | 6,000 | $4.19 | $25.1K | Form 4 |
| Aug 17, 2022 | Gagliano Nancy JDirector | Buy | 2,200 | $4.39 | $9.7K | Form 4 |
All 21 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Islet Management, LPSCHEDULE 13D, 1 filing Sep 17, 202671
- GAGNON SECURITIES LLCSCHEDULE 13G, 4 filings Nov 17, 2025 to Aug 12, 202672
- PRIVATE MANAGEMENT GROUP INCSCHEDULE 13G/A, 3 filings May 5, 2025 to Jul 31, 202673
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 30, 202674
- Altai Capital Management, L.P.SCHEDULE 13D/A, 5 filings Sep 9, 2025 to Apr 20, 202675
- VANGUARD GROUP INCSCHEDULE 13G/A, 6 filings Feb 10, 2022 to Mar 27, 202676
- DIMENSIONAL FUND ADVISORS LPSCHEDULE 13G/A, 2 filings Feb 9, 2024 to Oct 9, 202577
- EARNEST PARTNERS LLCSCHEDULE 13G/A, 2 filings Feb 8, 2022 to Sep 3, 202578
- Camber Capital Management LPSCHEDULE 13G/A, 3 filings Nov 8, 2021 to May 15, 202579
- BlackRockSCHEDULE 13G/A, 6 filings Jan 28, 2022 to Apr 23, 202580
- Neuberger BermanSCHEDULE 13G, 3 filings Oct 4, 2024 to Apr 4, 202581
- MANAGED ACCOUNT ADVISORS LLCSC 13G/A, 2 filings Jan 26, 2022 to Feb 7, 202382
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Carrie Eglinton Manner | 52 | $721.0K | $4.3M83 |
| 2025 | Kathleen G. Weber | $421.1K | $1.8M83 | |
| 2025 | Kenneth McGrath | 54 | $512.0K | $1.3M83 |
| 2024 | President and Chief Executive Officer | $721.0K | $5.6M83 | |
| 2024 | Chief Financial Officer | $497.5K | $1.7M83 | |
| 2024 | Former Chief Product Officer | $488.0K | $1.4M83 | |
| 2023 | President and Chief Executive Officer | $721.0K | $6.7M83 | |
| 2023 | Former Chief Product Officer | $473.8K | $1.7M83 | |
| 2023 | Chief Financial Officer | $483.0K | $1.5M83 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 6,256,762 | $27.9M | 0.0% | −259,454 |
| Neuberger Berman Group LLC | 4,685,432 | $20.9M | 0.0% | +323,531 |
| Private Management Group Inc | 3,797,682 | $16.9M | 0.4% | −1,624,447 |
| Vanguard Capital Management LLC | 3,018,907 | $13.5M | 0.0% | −11,981 |
| Systematic Financial Management LP | 2,857,974 | $12.7M | 0.3% | +377,491 |
| Dimensional Fund Advisors LP | 2,340,901 | $10.4M | 0.0% | −479,929 |
| First Eagle Investment Management, LLC | 2,125,500 | $9.5M | 0.0% | New |
| Renaissance Technologies LLC | 2,014,903 | $9.0M | 0.0% | −68,400 |
| Geode Capital Management, LLC | 1,807,889 | $8.1M | 0.0% | −12,130 |
| State Street Corp | 1,686,609 | $7.5M | 0.0% | −18,171 |
| Gagnon Securities LLC | 1,592,147 | $7.1M | 1.4% | −122,244 |
| Cannell Capital LLC | 1,427,419 | $6.4M | 4.4% | −575,852 |
| Gagnon Advisors, LLC | 1,207,440 | $5.4M | 3.4% | No change |
| Peapod Lane Capital LLC | 993,875 | $4.4M | 3.0% | −24,601 |
| Wells Fargo & Company/mn | 924,030 | $4.1M | 0.0% | +24,189 |
| Jacobs Levy Equity Management, Inc | 844,935 | $3.8M | 0.0% | −154,658 |
| D. E. Shaw & Co., Inc. | 827,187 | $3.7M | 0.0% | −555,201 |
| Archon Capital Management LLC | 747,909 | $3.3M | 1.4% | No change |
| Vanguard Portfolio Management LLC | 623,664 | $2.8M | 0.0% | +33,466 |
| Jpmorgan Chase & Co | 589,177 | $2.7M | 0.0% | +228,653 |
| Northern Trust Corp | 587,408 | $2.6M | 0.0% | −7,764 |
| Charles Schwab Investment Management Inc | 579,583 | $2.6M | 0.0% | −6,254 |
| Goldman Sachs Group Inc | 561,650 | $2.5M | 0.0% | +150,124 |
| Vanguard Fiduciary Trust Co | 458,067 | $2.0M | 0.0% | +3,292 |
| Tudor Investment Corp Et Al | 400,829 | $1.8M | 0.0% | +288,073 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How ORASURE TECHNOLOGIES INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARORASURE TECHNOLOGIES INC1
- CIK0001116463
- Employer ID (EIN)36-43709664
- Filer statusAccelerated filer not an emerging growth company; not a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address220 E First St, Bethlehem, PA 180151
- Phone50364161151
- Shares outstanding68,968,627 as of Jul 31, 202611
- Public float$218.5M as of Jun 30, 20254
- AuditorGRANT THORNTON LLP, Philadelphia, PA PCAOB ID 248; it also attests to the company’s internal control over financial reporting4
- On EDGAR sinceJun 14, 20001
- Filings1,482 in all: 4 (686), 8-K (315), SC 13G/A (85), 10-Q (78), SC 13G (34), 3 (32), DEFA14A (31), 10-K (26)1
All 43 form types
DEF 14A (26), UPLOAD (19), ARS (18), CORRESP (16), S-8 (16), S-3 (9), SCHEDULE 13G/A (9), S-3/A (8), 424B5 (6), 8-K/A (6), EFFECT (6), SCHEDULE 13G (6), CT ORDER (5), S-4/A (5), SC 13D (4), SCHEDULE 13D/A (4), 144 (3), 4/A (3), S-8 POS (3), 10-K/A (2), 10-Q/A (2), 5 (2), DFAN14A (2), PRE 14A (2), SC 13D/A (2), SCHEDULE 13D (2), 10-QT (1), 424B3 (1), 425 (1), 8-A12B (1), FWP (1), PX14A6G (1), S-4 (1), S-4 POS (1), SD (1)
- Latest filingsAnnual report (10-K) Mar 9, 2026
Quarterly report (10-Q) Aug 7, 2026
Proxy statement (DEF 14A) Apr 30, 2026
Latest 8-K (8-K) Aug 5, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.000001 par value per share | OSUR | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Mar 9, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks ORASURE TECHNOLOGIES INC names in Item 1A of its 10-K filed Mar 9, 2026: 68 risks under these headings, as written.4
- Risks Relating to Products, Marketing and Sales
- Risks Relating to the Company's Industry, Business and Strategy
- Risks Relating to the Company's Reliance on Third Parties
- Risks Relating to Intellectual Property
- Regulatory Risks
- Risks Relating to the Economy, Company Financial Results, Investments, Credit Facilities and Need for Financing
- Risks Relating to the Company's Common Stock
- General Risk Factors
- Changes in the Genomics Market May Adversely Affect the Company's Business.
- The Company's Future Success Depends Upon Market Acceptance of its Existing and Future Products and Service Offerings.
- If Acceptance and Adoption of Oral Fluid Testing and Collection Products Does Not Continue, the Company's Future Results May Suffer.
- The Company Expects to Face Increasing Competition From Other Providers of Diagnostic Tests and Sample Collection Products.
The other 63 risks
- The Company's Product Sales Cycles Can be Lengthy, and May Depend on Public Funding, Which Can Cause Variability and Unpredictability in the Company's Operating Results.
- The Company's Inability To Expand International Sales Could Adversely Affect its Business and Results of Operations.
- The Company's International Presence May Increase Its Risks and Expose Its Business to Regulatory, Cultural or Other Restraints.
- The Company's U.S. Government Contracts Require Compliance With Numerous Laws and Increases Its Risk and Liability.
- The Company's Inability to Manufacture Products in Accordance with Applicable Specifications, Performance Standards or Quality Requirements Could Adversely Affect Its Business.
- The Company's Business Will Suffer if It Does Not Effectively Manage Challenges to Its Manufacturing Processes and It May be Unable to Successfully Scale-Up Manufacturing of Its Products in Sufficient Quality and Quantity to Meet Demand, Which Would Negatively Impact Revenue Expectations.
- The Company's Business Results Depend on Its Ability to Manage Disruptions in Its Domestic and Global Supply Chains and Distribution Channels.
- Certain of the Company's Products Depend on Components From a Sole-Source Supplier, the Loss of Which Would Cause the Company to be Unable to Deliver Such Products.
- The Company's U.S. Government Contracts May Affect Its Intellectual Property Rights.
- The Company's U.S. Government Contracts and Related Administrative Processes Are Subject to Audits and Cost Adjustments by the Federal Government.
- The Company Expects Revenue Levels From its InteliSwab® COVID-19 Rapid Test to Continue to Decline.
- Marketing of the Company's COVID-19 Tests and Collection Kits Under EUAs from the FDA Is Subject To Certain Limitations and the Company Is Required To Maintain Compliance with the Terms of the EUA, Among Other Things, and the Continuance of the EUAs Is Subject To Government Discretion.
- Consolidation in the Healthcare Industry Could Adversely Affect the Company's Future Revenues and Operating Results.
- The Company's Research, Development and Commercialization Efforts May Not Succeed and Its Competitors May Develop and Commercialize More Effective or Successful Offerings.
- Customer Concentration Creates Risk for the Company's Business.
- The Company is Subject to Risks Related to Government Funding and Customer Ordering.
- Acquisitions or Investments May Not Generate the Expected Benefits and Could Disrupt the Company's Ongoing Business, Distract Its Management, Increase Its Expenses and Adversely Affect Its Business.
- The Company's Revenues Could be Affected by Third-Party Reimbursement Policies and Potential Cost Constraints.
- Changes in Healthcare Regulation Could Affect the Company's Revenues, Costs and Financial Condition.
- New or Changed Testing Guidelines Could Affect Sales of the Company's Diagnostic Products.
- Reductions in Government Funding and Research Budgets Could Adversely Affect the Company's Business and Financial Results.
- The Company's Failure to Maintain Existing Distribution Channels, or Develop New Distribution Channels, May Result in Lower Revenues.
- The Company May Need Strategic Partners to Assist in Developing and Commercializing Some of Its Products.
- The Company's Success Depends on Its Ability to Protect Its Proprietary Technology.
- The Company May Become Involved in Intellectual Property Disputes, Which Could Increase Its Costs and Limit or Eliminate Its Ability to Sell Products, Provide Services or Use Certain Technologies.
- The Need to Obtain Regulatory Approvals, Clearances, Authorizations or Certifications Could Increase the Company's Costs and Adversely Affect Its Financial Performance.
- Failure to Comply With FDA or Other Regulatory Requirements May Require the Company to Suspend Production or Sale of Its Products or Institute a Recall Which Could Result in Higher Costs and a Loss of Revenues.
- The Company's Inability to Respond to Changes in Regulatory Requirements Could Adversely Affect Its Business.
- The Company Is Subject to Numerous Government Regulations in Addition to FDA Requirements, Which Could Increase the Company's Costs and Affect Its Operations.
- Disruptions at the FDA and Other Government Agencies, Including Staffing Constraints, and Funding Uncertainty, Could Delay or Prevent the Development, Review, Approval, or Commercialization of Our Products and Adversely Affect Our Business.
- Failure to Comply With Privacy, Security and Breach Notification Regulations May Increase the Company's Costs.
- Failure to Comply With Data Protection Requirements or Privacy Laws Could Increase the Company's Costs.
- Changes In Tax Laws Or In Their Implementation Or Interpretation May Adversely Affect Us Or Our Investors.
- The Use of New And Evolving Technologies, Such As Artificial Intelligence (“AI”), In Our Offerings May Present Risks And Challenges That Can Impact Our Business Including by Posing Security Risks to Our Confidential Information, Proprietary Information, and Personal Data.
- FDA Regulation of Laboratory-Developed Tests and Genetic Testing Could Affect Demand For the Company's Products.
- The Company's International Sales Create Potential Exposure Under Anti-Corruption Laws.
- Risks Relating to the Economy, the Company's Financial Results, Investments, and Need for Financing
- The Company Has Experienced Losses in the Past and May Not Be Able to Again Achieve and Maintain Profitable Operations.
- Recent Volatility In Capital Markets and Lower Market Prices For the Company's Securities May Affect Its Ability to Access New Capital Through Sales of Shares of Its Common Stock or Issuance Of Indebtedness, Which May Materially Harm Its Liquidity, Limit Its Ability to Grow Its Business, Pursue Acquisitions or Improve Its Operating Infrastructure and Restrict Its Ability to Compete in Its Markets.
- Rising Inflation Rates Could Negatively Impact the Company's Revenues and Profitability if Increases in the Prices of Its Products or a Decrease in Consumer Spending Results in Lower Sales. In Addition, if the Company's Costs Increase and the Company Is Not Able to Pass Along These Price Increases to Its Customers, Its Net Income Would Be Adversely Affected, and the Adverse Impact May Be Material.
- Increasing Geopolitical and Economic Risk and Tariffs Could Negatively Affect Our Ability to Maintain Sales at Existing Levels
- An Impairment of Goodwill and Intangible Assets Could Reduce the Company's Earnings.
- Changes in Foreign Currency Exchange Rates Could Negatively Affect the Company's Operating Results.
- The Company's Stock Price Could Continue to be Volatile.
- Share Repurchases Could Increase the Volatility of the Trading Price of Our Common Stock and Diminish Our Cash Reserves, and We Cannot Guarantee That Our Stock Repurchase Program Will Enhance Long-Term Stockholder Value.
- Future Sales of the Company's Common Stock by Existing Stockholders, Executive Officers or Directors Could Depress the Market Price of Its Common Stock and Make It More Difficult for the Company to Sell Stock in the Future.
- Because the Company Does Not Intend to Pay Cash Dividends on Its Common Stock, an Investor in the Company's Common Stock Will Benefit Only if the Its Common Stock Appreciates in Value.
- Certain Provisions in the Company's Certificate of Incorporation and Bylaws and Under Delaware Law Could Make a Third-Party Acquisition of the Company Difficult.
- Our Business Could be Negatively Affected as a Result of Actions of Activist Stockholders.
- The Company May Face Product Liability Claims for Injuries Resulting From the Use of Its Products.
- Performance of the Company's Products May Affect Its Revenues, Stock Price and Reputation.
- Failure to Achieve the Company's Financial and Strategic Objectives Could Have a Material Adverse Impact on Its Business Prospects.
- If the Company Fails To Establish and Maintain Proper And Effective Internal Control Over Financial Reporting, Its Operating Results and Its Ability to Operate Its Business Could Be Harmed.
- If the Company Loses Key Personnel or Is Unable to Attract and Retain Qualified Personnel as Necessary, Its Business Could be Harmed.
- Increases in Demand for the Company's Products and Services Could Require It to Expend Considerable Resources or Harm Its Customer Relationships if It Is Unable to Meet That Demand.
- The Company Relies on Information Technology in Its Operations and Any Material Failure, Inadequacy, Interruption or Security Breach of that Technology Could Harm Its Ability to Efficiently Operate Its Business.
- Cybersecurity Incidents and Other Disruptions Could Compromise the Company's Information, Expose It to Liability and Harm Its Reputation and Business.
- Federal and State Laws Pertaining to Healthcare Fraud and Abuse Could Adversely Affect the Company's Business, Financial Condition and Results of Operations.
- The Company May Experience Fluctuations in Its Financial Results or Fail to Meet Its Financial Projections.
- The Company May Require Future Additional Capital.
- Conditions in the Banking System and Financial Markets, Including the Failure of Banks and Financial Institutions, Could Have an Adverse Effect on the Company's Operations and Financial Results.
- Terrorist Attacks, Natural Disasters, Public Health Crises, Political Unrest or Other Catastrophic Events Outside of the Company's Control May Adversely Affect Its Business.
- Future Sales of Shares of the Company's Common Stock Could Adversely Affect the Trading Price of Its Common Stock and Its Ability to Raise Funds in New Equity Offerings.
Legal proceedings
Discussion of legal matters is incorporated by reference from Note 14, Commitments and Contingencies, to the Consolidated Financial Statements included in this Annual Report on Form 10-K.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARKathleen Gallagher Weber, President
- 15SEC EDGARLisa Nibauer, President
- 16
- 17
- 18
- 19
- 20
- 21SEC EDGARNancy J. Gagliano, Director
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29SEC EDGARMark L. Kuna, VP & Controller
- 30
- 31SEC EDGARStephen R. Lee, Exec. VP and CSO
- 32SEC EDGARJohn D. Bertrand, Board member
- 33SEC EDGARJohn P. Kenny, Board member
- 34SEC EDGARRobert W. McMahon, Board member
- 35SEC EDGARAnne Clem Whitaker, Board member
- 36SEC EDGARNancy J. Gagliano, Board member
- 37SEC EDGARDavid Shulkin, Board member
- 38SEC EDGARLelio Marmora, Board member
- 39SEC EDGARJames A. Datin, Board member
- 40SEC EDGARAradhana Sarin, Board member
- 41SEC EDGARMara G. Aspinall, Board member
- 42SEC EDGAREamonn P. Hobbs, Board member
- 43SEC EDGARGerald M. Ostrov, Board member
- 44SEC EDGARCharles W. Patrick, Board member
- 45SEC EDGARDouglas G. Watson, Board member
- 46SEC EDGARFrank G. Hausmann, Board member
- 47SEC EDGARRoger L. Pringle, Board member
- 48SEC EDGARRonny B. Lancaster, Board member
- 49SEC EDGARJack Goldstein, Board member
- 50SEC EDGARMichael Celano, Board member
- 51SEC EDGARAgnieszka Gallagher, General counsel
- 52SEC EDGARJack E. Jerrett, General counsel
- 53SEC EDGARStephen R. Lee, General counsel
- 54SEC EDGARResults of operations
- 55SEC EDGAROther events
- 56
- 57
- 58
- 59SEC EDGARRegulation FD disclosure
- 60SEC EDGARExecutive or director change
- 61
- 62
- 63SEC EDGAROther events
- 64
- 65SEC EDGARExecutive or director change
- 66NasdaqNasdaq calendar
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83